R&D channel feed

Biotech uni­corn Mod­er­na gam­bles $110M on a ground­break­ing mR­NA man­u­fac­tur­ing fa­cil­i­ty, blue­prints plant #2

9 years ago
Financing

Evotec signs up for a 5-year dis­cov­ery deal with Bay­er fo­cused on chron­ic kid­ney dis­ease

9 years ago

Genen­tech dives in­to mR­NA, bet­ting $310M on BioN­Tech's per­son­al­ized can­cer vac­cine tech

9 years ago
Pharma

Mast’s sick­le cell drug flunks PhI­II, eclips­ing shares

9 years ago

Pri­do­pi­dine is still a mess in lat­est Hunt­ing­ton’s study, but Te­va maps PhI­II

9 years ago

Te­va inks $2.6B deal to buy in­to Re­gen­eron’s PhI­II NGF pain drug

9 years ago

Scoop: J&J con­firms that the FDA put AML drug on com­plete hold

9 years ago

Ben­itec’s aban­doned one-dose hep C “cure” ac­tu­al­ly had two big prob­lems

9 years ago

Lead vac­cine from Vi­cal and Astel­las flops in a Phase II her­pes study

9 years ago

Am­gen’s ex­pec­ta­tions for ro­mosozum­ab take a hit as Ra­dius lines up its ri­val os­teo­poro­sis drug

9 years ago

No­var­tis shows a hole card in a high-stakes PhI­II pok­er game for MS drugs

9 years ago

No­vo’s big re­veal: GLP-1 drug semaglu­tide cuts car­dio risks, but just may blind you

9 years ago

Am­gen, No­var­tis cel­e­brate promis­ing mi­graine da­ta, but Te­va and Alder are prepar­ing to crash the par­ty

9 years ago

No­vavax shares are rout­ed af­ter its big PhI­II RSV vac­cine tri­al flops

9 years ago

Mer­ck, Pfiz­er tout PhI­II di­a­betes da­ta as er­tugli­fozin heads to the FDA

9 years ago

Rigel co-founder, R&D staff jet­ti­soned in the long-await­ed lead up to an FDA pitch

9 years ago

Ei­sai launch­es biotech di­vi­sion in Mass­a­chu­setts aimed at Alzheimer’s, I/O and au­toim­mune dis­eases

9 years ago

Acel­Rx takes an­oth­er step in its re­cov­ery pro­gram, prep­ping a pain med pitch to the FDA

9 years ago

Aerie shares rock­et up as glau­co­ma com­bo drug scores pos­i­tive da­ta

9 years ago

Agios sets out to raise $150M; AC Im­mune IPO sets val­u­a­tion at $700M

9 years ago
News Briefing

Roche’s megablock­buster MS can­di­date ocre­lizum­ab posts promis­ing head-to-head da­ta

9 years ago

At­las part­ner Sa­ha takes the helm at Delinia, look­ing to dis­rupt au­toim­mune R&D

9 years ago

On a spree, Al­ler­gan forks over a big pre­mi­um to nab Vi­tae’s au­toim­mune drugs for $639M

9 years ago

Yale’s David Spiegel in­spires an­oth­er im­muno-on­col­o­gy R&D spin­out fo­cused on An­ti­body Re­cruit­ing Mol­e­cules

9 years ago
People
First page Previous page 318319320321322323324 Next page Last page
A service from the Financial Times